Interestingly, this study demonstrated that nivolumab treatment significantly reduced the production of IL-10 by T cells under glucose deprived hypoxic conditions compared with untreated cells under glucose deprived hypoxic conditions, suggesting that PD-1 blockade may help skew T cells toward an anti-tumour phenotype within the OAC TME. This evidence concerns the gene IL10 and neoplasm.